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Chondroitin Sulfate Proteoglycans Are Associated with the Lesions 
of Alzheimer's Disease 
DAVID A. DEWITT,* JERRY SILVER,* DAVID R. CANNING,* AND GEORGE PERRy*'t 
*Department of Neurosciences and tDivision of Neuropathology, Institute of Pathology 
Case Western Reserve University, Cleveland, Ohio 44106-4901 
Chondroitin sulfate proteoglycans (CSPG) are extra-
cellular matrix proteins inhibitory to neurite out-
growth in vitro and correlated with decreased neurite 
outgrowth after CNS injury. Previously, heparan sul-
fate proteoglycan and dermatan sulfate proteoglycan 
have been shown to be associated with senile plaques 
(SPs) and neurofibrillary tangles (NFTs) but CSPG was 
not. In an immunocytochemical study, three monoclo-
nal antibodies to different sulfation states of the chon-
droitin glycosaminoglycan were used to localize CSPG 
in cases of Alzheimer's disease. Chondroitin 4-sulfate 
was found in both SPs and NFTs. An antibody to unsul-
fated chondroitin strongly immunostained intracellu-
lar NFTs and the dystrophic neurites of SPs. Chondroi-
tin 6-sulfate was found in NFTs and the area around 
SPs. These results suggest that CSPG, in addition or as 
an alternative to ~-amyloid protein, could be responsi-
ble for the regression of neurites around senile plaques 
in Alzheimer's disease. © 1993 Academic Press, Inc. 
INTRODUCTION 
Alzheimer's disease is a severe mentally debilitating 
disease characterized by two principle lesions, the neuro-
fibrillary tangle (NFT) and the senile plaque (SP). Se-
nile plaques consist of a core of amyloid {3-protein (A{3), 
a 39- to 42-amino acid peptide (13) derived from a larger 
amyloid precursor protein (APP) (8). Dystrophic neu-
rites containing APP (9) and processes of reactive as-
trocytes extend radially toward the A{3 core. Whether 
the neurites are growing into the SP or are dying and/or 
moving away from the plaque has not been determined. 
The status of neurites is compounded by in vitro studies 
in which A{3 has been shown to have both trophic and 
toxic effects on neurons (29). 
Proteoglycans are highly anionic proteins with one or 
mOre glycosaminoglycans attached to the protein core. 
They are one of the principle components of the extra-
cellular matrix. Enzymatic digestion of glycosaminogly-
cans leaves a distinct antigenic sugar stub specific for 
each type of glycan. 
APP has been shown to be involved in the growth 
regulation of different cell types (12, 17). In cultured 
neurons, APP has been shown to be associated with the 
extracellular matrix (11) and to mediate cell-cell and 
cell-surface adhesion (4). Recently, APP was shown to 
be a chondroitin sulfate proteoglycan core protein (19). 
While the presence of chondroitin 4-sulfate (C-4) was 
determined associated with APP, neither chondroitin 
6-sulfate (C-6) nor un sulfated chondroitin (C-O) was 
found attached to APP. 
Chondroitin sulfate proteoglycans (CSPGs), C-6 in 
particular, can inhibit neurite outgrowth in vitro (23, 
24). CSPG may serve as an inhibitory barrier during 
development providing for axon guidance (5). In adult 
animals, CSPGs and reactive astrocytes have been 
correlated with decreased neurite outgrowth in re-
sponse to injury to the central nervous system (14). 
Glial cells make and secrete CSPGs (15, 19). Addition-
ally, a subpopulation of neurons have CSPG lining their 
perimeter (3). The exact function of this neuronal pro-
teoglycan is unknown. 
Previously, proteoglycans have been found in SPs 
and NFTs. Heparan sulfate proteoglycan has been 
found in both SPs (21, 22, 26) and NFTs (16, 18, 26). 
Decorin, a dermatan sulfate proteoglycan, was reported 
to line the periphery of SPs and was localized to paired 
helical filaments within NFTs (20). However, CSPGs 
have not previously been found in either lesion. 
In this immunohistochemistry study, we demonstrate 
the presence of three differentially sulfated CSPGs in 
the lesions of Alzheimer's disease. 
MATERIALS AND METHODS 
Sections from frontal cortex or hippocampus from six 
cases of Alzheimer's disease confirmed by pathological 
examination (ages 69-85; postmortem interval 2-7 h) 
and two controls (ages 57 and 78; postmortem interval 
15-18 h) were studied. Tissue was fixed in methacarn 
(methanol:chloroform:acetic acid, 6:3:1) and embedded 
in parafin. Immunostaining was done by the peroxidase 
anti-peroxidase method with 3',3'-diaminobenzidine as 
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the cosubstrate (25). To detect C-6 CSPG core protein, 
the monoclonal antibody 3B3 was used (7). Methacarn-
fixed sections were incubated with chondroitinase ABC 
(ICN) or with chondroitinase AC (Sigma) in Tris-ace-
tate buffer (pH 8 and pH 7.6, respectively) for 2 h at 
37°C or overnight at 20°C followed by overnight incu-
bation at 4°C with antibody. Heparinase and heparitin-
ase treatments were also used as controls. SPs were ver-
ified by Congo red or staining adjacent sections with 
4G8, (10) a monoclonal antibody to AfJ. Antibodies to 
C-O and C-4 (IB5 and 2B6, respectively) were used to 
determine whether these forms of CSPG were also pres-
ent. NFTs were identified by double immunostaining 
with an antisera to T (27). Anti-T utilized biotin-avidin-
conjugated alkaline phosphatase with Fast Blue as the 
substrate. 
RESULTS 
The antibody to unsulfated chondroitin strongly 
stained dystrophic neurites around SPs (Fig. ID) and 
intracellular NFTs (Figs. lA and ID). The staining of 
NFTs was distinct from other neurons in the same sec-
tion and from controls. Consistent with a previous re-
port (3) a subset of neurons stained for unsulfated 
chondroitin as a wide band along the neural perimeter 
(data not shown). 
Chondroitin 4-sulfate was localized to the perimeter 
of Congo red-positive SPs (Fig. IH), NFTs (Fig. IB), 
and dystrophic neurites (Figs. IE and IF). In order to 
verify that the 2B6 antibody was recognizing C-4 in-
stead of dermatan sulfate, the sections were treated 
with chondroitinase AC, which does not digest derma-
tan sulfate (28). There was no apparent difference in 
staining between either chondroitinase enzyme treat-
ment (Figs. IE and IF) which suggests that chondroitin 
4-sulfate is in fact associated with both SPs and NFTs. 
C-6 was localized with the 3B3 antibody. Intense 
staining was found at the immediate periphery of AfJ 
deposits in senile plaques (Fig. IG). In addition, more 
diffuse staining occurred further out around the SPs. 
Most of the C6 immunoreactivity around SPs appeared 
as an extracellular deposit around the SP. SPs were 
identified by Congo red (Fig. 11) and adjacent sections 
stained with 4G8, an antibody which recognizes AfJ. C-6 
CSPG was also localized to T-positive NFTs (Fig. lC). 
C-4 and C-6 were predominately confined to the area 
around the SP core-the same area as dystrophic neu-
rites and astrocytic processes although diffuse, light 
staining occurred throughout the neuropil. None of the 
chondroitin antibodies stained the core. Essentially 
every NFT immunostained for T was also stained for all 
three CSPGs with the CSPG staining much stronger, 
making identification of T sometimes difficult. Almost 
without exception these NFTs were intraneuronal since 
the cytoplasm surrounding nuclei was apparent, indi-
cating that CSPG is associated primarily with intraneu-
ronal tangles. None of the antibodies to CSPG immuno-
stained any structure without previously treating the 
sections with chondroitinase to digest the sugars. 
Treatment with heparinase or heparitinase did not re-
sult in staining by the antibodies either. Immunoblots of 
A68, T, ubiquitin, P-component, and neurofilaments did 
not show binding of chondroitin antibodies with or 
without chondroitinase digestion. 
DISCUSSION 
In this study, we have demonstrated the presence of 
three differentially sulfated CSPGs in the lesions of 
Alzheimer's disease. Unsulfated chondroitin, chondroi-
tin 4-sulfate, and chondroitin 6-sulfate were all found 
associated with SPs, NFTs, and dystrophic neurites. 
Prior reports indicated that dermatan sulfate was 
present in senile plaques and NFTs (20) while chon-
droitin sulfate was not (21). The antibodies used in 
these previous studies to identify chondroitin sulfate 
were raised to the glycosaminoglycan chains of CSPG. 
We also saw no immunoreactivity with antibodies 
raised to the CSPG sugar residues (data not shown). 
Here, antibodies which recognize the chondroitinase-di-
gested stub have been shown to recognize both SPs and 
NFTs. Perhaps the sugar residues are masked by an-
other protein or proteoglycan which prevents antibody 
binding but not enzyme activity, thus allowing for expo-
sure of the digested epitope. 
Enzymatic digestion with chondroitinase AC specifi-
cally demonstrates the presence of C-4 as opposed to 
dermatan sulfate. Chondroitinase ABC digests both 
chondroitin and dermatan sulfate sugars while chon-
droitinase AC only digests chondroitin. Since both en-
zymes yielded a similar staining pattern, the antibody is 
recognizing chondroitin. Dermatan sulfate would not be 
stained after chondroitinase AC treatment. These re-
sults suggest that C-4 is present in SPs and NFTs. The 
3B3 antibody to C-6 can also bind to C-O albeit with a 
much lower affinity (1). IB5, which specifically binds to 
C-O sites, did not stain SPs as strongly as 3B3 or with 
the same pattern, suggesting that the immunolocaliza-
tion of 3B3 is specific for C-6, at least around SPs. 
The presence of C-6 around SPs is significant because 
this glycosaminoglycan is particularly associated with 
decreased neurite outgrowth in vitro and in response to 
injury within the central nervous system. Large 
amounts of C-6 around SPs could deter neurites from 
growing in toward the SPs and may actually be causing 
or mediating neuritic dystrophy. Interestingly, the area 
which contains C6 immunoreactivity around the SP 
overlaps with the area known to show a decrease in 
neuritic density (2). Abnormal CSPG accumulation 
could disrupt cell adhesion or growth factor utilization. 
It is unclear whether each antibody is recognizing a 
different CSPG core protein or the same core protein 
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FIG. 1. Neurofibrillary tangles were identified with antisera to r (purple). Sections were treated with chondroitinase ABC prior to 
addition of antibody. Monoclonal antibodies indicate different sulfation states of chondroitin sulfate proteoglycan (brown). Unsulfated 
chondroitin (A), chondroitin 4-sulfate (B), and chondroitin 6-sulfate (C) are present in intracellular neurofibrillary tangles (N, nucleus). 
CSPG can be found in the periphery of senile plaques. Note the absence ofCSPG immunoreactivity in A,B core of the senile plaque (c, core in D 
through I). Dystrophic neurites are immunostained for r (D through G, arrows). Unsulfated chondroitin primarily stained dystrophic neurites 
(D) and neurofibrillary tangles (arrowheads). Chondroitin 4-sulfate CSPG occurred with both chondroitinase ABC (E) and chondroitinase AC 
(F). Chondroitin 6-sulfate surrounds the A,B core (G). Senile plaques immunostained for CSPG were verified by Congo red (H and I). Congo red 
birefringence of the A,B core is seen as a green and yellow cross under polarized light. Scale bars = 20 /Lm. 
with differentially sulfated chondroitin. Additionally, 
. the same proteins could have other glycosaminoglycans 
n?t digested by chondroitinase. These questions are sig-
nificant because there could be multiple sources in brain 
for the different CSPGs or different forms may occur at 
various stages of neuronal degeneration. 
We have found in additional studies that astrocytes 
accumulate CSPGs in response to AfJ (6), therefore, glia 
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may be the source for some of the CSPGs. However, 
since primarily intraneuronal NFTs were also stained, a 
potential source of CSPG could be neuronal. In the case 
of NFTs, CSPG accumulation may occur concurrently 
with NFT formation. In the vicinity of SPs, both neu-
rons and glia could interact synergisticly and accumu-
late various proteoglycans to produce a terrain refrac-
tory to neural regeneration. 
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